1. Home
  2. ADVM vs CXDO Comparison

ADVM vs CXDO Comparison

Compare ADVM & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • CXDO
  • Stock Information
  • Founded
  • ADVM 2006
  • CXDO 1995
  • Country
  • ADVM United States
  • CXDO United States
  • Employees
  • ADVM N/A
  • CXDO N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • CXDO Telecommunications Equipment
  • Sector
  • ADVM Health Care
  • CXDO Telecommunications
  • Exchange
  • ADVM Nasdaq
  • CXDO Nasdaq
  • Market Cap
  • ADVM 119.6M
  • CXDO 139.6M
  • IPO Year
  • ADVM 2014
  • CXDO 1998
  • Fundamental
  • Price
  • ADVM $4.74
  • CXDO $5.25
  • Analyst Decision
  • ADVM Strong Buy
  • CXDO Strong Buy
  • Analyst Count
  • ADVM 6
  • CXDO 2
  • Target Price
  • ADVM $27.83
  • CXDO $6.50
  • AVG Volume (30 Days)
  • ADVM 226.5K
  • CXDO 163.5K
  • Earning Date
  • ADVM 11-04-2024
  • CXDO 11-06-2024
  • Dividend Yield
  • ADVM N/A
  • CXDO N/A
  • EPS Growth
  • ADVM N/A
  • CXDO N/A
  • EPS
  • ADVM N/A
  • CXDO 0.05
  • Revenue
  • ADVM $1,000,000.00
  • CXDO $58,762,000.00
  • Revenue This Year
  • ADVM N/A
  • CXDO $15.52
  • Revenue Next Year
  • ADVM $1,342.84
  • CXDO $10.52
  • P/E Ratio
  • ADVM N/A
  • CXDO $110.12
  • Revenue Growth
  • ADVM N/A
  • CXDO 16.41
  • 52 Week Low
  • ADVM $4.59
  • CXDO $2.92
  • 52 Week High
  • ADVM $29.70
  • CXDO $7.59
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 26.02
  • CXDO 51.38
  • Support Level
  • ADVM $4.59
  • CXDO $4.70
  • Resistance Level
  • ADVM $4.89
  • CXDO $5.40
  • Average True Range (ATR)
  • ADVM 0.31
  • CXDO 0.28
  • MACD
  • ADVM -0.06
  • CXDO 0.01
  • Stochastic Oscillator
  • ADVM 9.80
  • CXDO 62.25

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

About CXDO Crexendo Inc.

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of revenue from the Cloud telecommunications segment.

Share on Social Networks: